FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2296957447> ?p ?o ?g. }

• W2296957447 abstract "IntroductionPatients with the same stage of malignancy often have different life-span, which makes it necessary to search for new prognostic factors.The high incidence and low survival rate of patients with gastric cancer also cause an increased interest in studying the immunohistochemical profile of tumors of the stomach. Recently, researchers are studying the prognostic significance of immunohistochemical markers such as: EGFR [10], VEGF [12,15,18], HER2/neu [8,17,19], expression of betakatenin [1], hERG1 [7], p53 [14], PCNA [14,20]Of particular interest is the HER2/neu. Overexpression of HER2/neu promotes tumor growth and plays an important role in the pathogenesis of some human malignancies [17].Nevertheless, the impact of HER2/neu status on the prognosis of patients with gastric cancer remains controversial [6,11,19]. Nakajima Garcia and colleagues believe that the increased expression of HER2/neu in patients with gastric cancer correlates with poor prognosis and more aggressive disease [11]. At the same time, Begnami found that life expectancy in gastric cancer patients with HER-2/neu-positively stained tumors was significantly shorter than in patients with HER-2/neu-negatively stained tumors (17 months vs. 40 months, respectively, p=0.023) [5].The aim of researchStudy the prognostic significance of immunohistochemical marker HER-2/neu in patients resected for gastric cancer stage IIIA.Materials and methodsMaterials for the study were histologic surgical specimens of the primary tumor in 21 patients who had surgery in the Zaporozhye Regional Clinical Oncology Center due to stomach cancer stage IIIA, including 14 men (67%) and 7 females (33%).Patients underwent surgery in the volume: gastrectomy and distal subtotal resection, 86% of patients received adjuvant chemotherapy of standard schemes.Immunohistochemical study of HER2/neu (erbB-2) used a rabbit polyclonal antibody. Immunohistochemical reaction was evaluated as negative in the absence of expression of membrane receptors or HER2/neu coloring immunopositive less than 5% of tumor cells (- - no reaction) as low positive - in the presence of 6-10 % of tumor cells immunopositive (+), moderately positive - 10-50% (++) and high pozitive - 50% positive tumor cells (+++). For further comparative immunohistochemical study identified two main levels of immunoreactivity: low or reduced protein expression (-/+) and high level or overexpression of the marker (++/+++).To assess survival used the Kaplan - Meier. Comparison of survival curves was performed using the Cox-F test.ResultsThe largest group of patients with gastric cancer stage IIIA consisted of patients with a negative reaction to the presence of receptor HER2/neu (47,6%), the second place is a group of patients with moderately positive reaction - 23.8%, patients with low positive and high pozitive reactions were equally divided - by 14.3%.Median survival of patients with gastric cancer stage IIIA was 19.8 months.The study two groups of patients with a low level or reduced protein expression (-/+) and high level or overexpression of the marker (++/+++) showed a higher survival rate in the former group (median survival was 50 months) compared to the second group, where the median was equal to 16 months (p<0.05).Conclusion1. Median survival of patients with gastric cancer operated stage IIIA was on average 19.8 months.2. High level or overexpression of marker HER2/neu (++/+++) is bad prognostic sign for life expectancy of patients with stage IIIA (p<0.05).3. The prospect of further study is research of the prognostic value of marker HER2/neu in patients with gastric cancer stages I and II." @default.
• W2296957447 created "2016-06-24" @default.
• W2296957447 creator A5075025411 @default.
• W2296957447 date "2014-06-19" @default.
• W2296957447 modified "2023-09-27" @default.
• W2296957447 title "Prognostic value of immunohistochemical marker HER2/neu in patients resected for gastric cancer stage IIIA" @default.
• W2296957447 doi "https://doi.org/10.14739/2310-1210.2014.2.25417" @default.
• W2296957447 hasPublicationYear "2014" @default.
• W2296957447 type Work @default.
• W2296957447 sameAs 2296957447 @default.
• W2296957447 citedByCount "0" @default.
• W2296957447 crossrefType "journal-article" @default.
• W2296957447 hasAuthorship W2296957447A5075025411 @default.
• W2296957447 hasBestOaLocation W22969574471 @default.
• W2296957447 hasConcept C121608353 @default.
• W2296957447 hasConcept C126322002 @default.
• W2296957447 hasConcept C142724271 @default.
• W2296957447 hasConcept C143998085 @default.
• W2296957447 hasConcept C146357865 @default.
• W2296957447 hasConcept C151730666 @default.
• W2296957447 hasConcept C204232928 @default.
• W2296957447 hasConcept C2776872082 @default.
• W2296957447 hasConcept C2779399171 @default.
• W2296957447 hasConcept C2779422922 @default.
• W2296957447 hasConcept C530470458 @default.
• W2296957447 hasConcept C63363279 @default.
• W2296957447 hasConcept C71924100 @default.
• W2296957447 hasConcept C86803240 @default.
• W2296957447 hasConcept C90924648 @default.
• W2296957447 hasConceptScore W2296957447C121608353 @default.
• W2296957447 hasConceptScore W2296957447C126322002 @default.
• W2296957447 hasConceptScore W2296957447C142724271 @default.
• W2296957447 hasConceptScore W2296957447C143998085 @default.
• W2296957447 hasConceptScore W2296957447C146357865 @default.
• W2296957447 hasConceptScore W2296957447C151730666 @default.
• W2296957447 hasConceptScore W2296957447C204232928 @default.
• W2296957447 hasConceptScore W2296957447C2776872082 @default.
• W2296957447 hasConceptScore W2296957447C2779399171 @default.
• W2296957447 hasConceptScore W2296957447C2779422922 @default.
• W2296957447 hasConceptScore W2296957447C530470458 @default.
• W2296957447 hasConceptScore W2296957447C63363279 @default.
• W2296957447 hasConceptScore W2296957447C71924100 @default.
• W2296957447 hasConceptScore W2296957447C86803240 @default.
• W2296957447 hasConceptScore W2296957447C90924648 @default.
• W2296957447 hasIssue "2" @default.
• W2296957447 hasLocation W22969574471 @default.
• W2296957447 hasOpenAccess W2296957447 @default.
• W2296957447 hasPrimaryLocation W22969574471 @default.
• W2296957447 hasRelatedWork W2013203421 @default.
• W2296957447 hasRelatedWork W2053551177 @default.
• W2296957447 hasRelatedWork W2327662849 @default.
• W2296957447 hasRelatedWork W2382097547 @default.
• W2296957447 hasRelatedWork W2391631919 @default.
• W2296957447 hasRelatedWork W2398874641 @default.
• W2296957447 hasRelatedWork W2408796791 @default.
• W2296957447 hasRelatedWork W2408845294 @default.
• W2296957447 hasRelatedWork W2416922755 @default.
• W2296957447 hasRelatedWork W2423788337 @default.
• W2296957447 hasVolume "0" @default.
• W2296957447 isParatext "false" @default.
• W2296957447 isRetracted "false" @default.
• W2296957447 magId "2296957447" @default.
• W2296957447 workType "article" @default.